The human longevity gene homolog INDY and interleukin-6 interact in hepatic lipid metabolism

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Christian von Loeffelholz - , Friedrich-Schiller-Universität Jena (Autor:in)
  • Stefanie Lieske - , Technische Universität Dresden, Universität Potsdam (Autor:in)
  • Frank Neuschäfer-Rube - , Universität Potsdam (Autor:in)
  • Diana M. Willmes - , Technische Universität Dresden (Autor:in)
  • Nathanael Raschzok - , Charité – Universitätsmedizin Berlin (Autor:in)
  • Igor M. Sauer - , Charité – Universitätsmedizin Berlin (Autor:in)
  • Jörg König - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Martin F. Fromm - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Paul Horn - , Friedrich-Schiller-Universität Jena (Autor:in)
  • Antonios Chatzigeorgiou - , Technische Universität Dresden (Autor:in)
  • Andrea Pathe-Neuschäfer-Rube - , Universität Potsdam (Autor:in)
  • Jens Jordan - , Universität zu Köln (Autor:in)
  • Andreas F.H. Pfeiffer - , Charité – Universitätsmedizin Berlin, Deutsches Zentrum für Diabetesforschung (DZD e.V.) (Autor:in)
  • Geltrude Mingrone - , King's College London (KCL), Catholic University of the Sacred Heart (Autor:in)
  • Stefan R. Bornstein - , Medizinische Klinik und Poliklinik III, King's College London (KCL), Deutsches Zentrum für Diabetesforschung (DZD e.V.) (Autor:in)
  • Peter Stroehle - , Max Planck Institute for Metabolism Research (Autor:in)
  • Christoph Harms - , Charité – Universitätsmedizin Berlin (Autor:in)
  • F. Thomas Wunderlich - , Max Planck Institute for Metabolism Research (Autor:in)
  • Stephen L. Helfand - , Brown University (Autor:in)
  • Michel Bernier - , National Institutes of Health (NIH) (Autor:in)
  • Rafael de Cabo - , National Institutes of Health (NIH) (Autor:in)
  • Gerald I. Shulman - , Yale University (Autor:in)
  • Triantafyllos Chavakis - , Institut für Klinische Chemie und Laboratoriumsmedizin (Autor:in)
  • Gerhard P. Püschel - , Universität Potsdam (Autor:in)
  • Andreas L. Birkenfeld - , Medizinische Klinik und Poliklinik III, Deutsches Zentrum für Diabetesforschung - Paul Langerhans Institut Dresden (Partner: HMGU), King's College London (KCL), Study Center for Metabolic Vascular Medicine, Deutsches Zentrum für Diabetesforschung (DZD e.V.) (Autor:in)

Abstract

Reduced expression of the Indy (“I am Not Dead, Yet”) gene in lower organisms promotes longevity in a manner akin to caloric restriction. Deletion of the mammalian homolog of Indy (mIndy, Slc13a5) encoding for a plasma membrane–associated citrate transporter expressed highly in the liver, protects mice from high-fat diet–induced and aging-induced obesity and hepatic fat accumulation through a mechanism resembling caloric restriction. We studied a possible role of mIndy in human hepatic fat metabolism. In obese, insulin-resistant patients with nonalcoholic fatty liver disease, hepatic mIndy expression was increased and mIndy expression was also independently associated with hepatic steatosis. In nonhuman primates, a 2-year high-fat, high-sucrose diet increased hepatic mIndy expression. Liver microarray analysis showed that high mIndy expression was associated with pathways involved in hepatic lipid metabolism and immunological processes. Interleukin-6 (IL-6) was identified as a regulator of mIndy by binding to its cognate receptor. Studies in human primary hepatocytes confirmed that IL-6 markedly induced mIndy transcription through the IL-6 receptor and activation of the transcription factor signal transducer and activator of transcription 3, and a putative start site of the human mIndy promoter was determined. Activation of the IL-6–signal transducer and activator of transcription 3 pathway stimulated mIndy expression, enhanced cytoplasmic citrate influx, and augmented hepatic lipogenesis in vivo. In contrast, deletion of mIndy completely prevented the stimulating effect of IL-6 on citrate uptake and reduced hepatic lipogenesis. These data show that mIndy is increased in liver of obese humans and nonhuman primates with NALFD. Moreover, our data identify mIndy as a target gene of IL-6 and determine novel functions of IL-6 through mINDY. Conclusion: Targeting human mINDY may have therapeutic potential in obese patients with nonalcoholic fatty liver disease. German Clinical Trials Register: DRKS00005450. (Hepatology 2017;66:616–630).

Details

OriginalspracheEnglisch
Seiten (von - bis)616-630
Seitenumfang15
FachzeitschriftHepatology
Jahrgang66
Ausgabenummer2
PublikationsstatusVeröffentlicht - Aug. 2017
Peer-Review-StatusJa

Externe IDs

researchoutputwizard legacy.publication#78841
Scopus 85014417037
PubMed 28133767

Schlagworte

Ziele für nachhaltige Entwicklung

ASJC Scopus Sachgebiete